Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03272009
Recruitment Status : Completed
First Posted : September 5, 2017
Last Update Posted : August 21, 2018
Sponsor:
Collaborator:
CPR Pharma Services Pty Ltd, Australia
Information provided by (Responsible Party):
Enyo Pharma

Brief Summary:

Bile acids regulating farnesoid X receptor (FXR) interact with hepatitis B virus replication. EYP001a is a selective, synthetic FXR agonist under development for the treatment of hepatitis B.

This Phase 1b study is designed primarily to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of EYP001a in chronically HBV infected subjects.


Condition or disease Intervention/treatment Phase
Hepatitis B, Chronic Drug: EYP001a Drug: Placebo Drug: Entecavir Drug: peg-interferon alfa-2a Phase 1

Detailed Description:

This is a multicenter, randomized, double-blind, placebo-controlled two-part trial.

In Part A, EYP001a will be administered as 29 days monotherapy. Three dose-levels and 2 dosing regimens of EYP001a will be explored against placebo. The design also includes an open-label standard of care Entecavir monotherapy arm (comparator). Subjects will be randomly assigned to one of the 6 treatment arms:

  • Treatment A: oral EYP001a
  • Treatment B: oral EYP001a
  • Treatment C: oral EYP001a
  • Treatment D: oral EYP001a
  • Treatment E: oral placebo
  • Treatment F: oral Entecavir

In Part B, EYP001a or placebo will be administered as 29 days combination therapy with the standard of care Peg-IFNα2a. Subjects will be randomly assigned to one of the 3 treatment arms:

  • Treatment G: oral EYP001a plus open label Peg-INFα2a administered as subcutaneous injection
  • Treatment H: oral EYP001a plus open label Peg-INFα2a administered as subcutaneous injection
  • Treatment I: oral placebo plus open label Peg-INFα2a administered as subcutaneous injection

Subjects enrolled in Part A are eligible for participation in Part B.

Participation will include a 40 day screening period, a 29 day treatment period and a 6 day follow-up evaluation period. For subjects who participate in both Parts A and B, a 14 washout period between Parts A and B will be included.

The safety and tolerability of EYP001a will be assessed by evaluating physical examinations, vital signs, ECGs, clinical laboratory parameters, and adverse events.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 73 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the FXR-agonist EYP001a in Chronically HBV Infected Subjects
Actual Study Start Date : September 21, 2017
Actual Primary Completion Date : July 30, 2018
Actual Study Completion Date : July 30, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treatment A
oral EYP001a
Drug: EYP001a
Capsules administered orally. Number of morning and evening capsules depending on treatment arm

Experimental: Treatment B
oral EYP001a
Drug: EYP001a
Capsules administered orally. Number of morning and evening capsules depending on treatment arm

Experimental: Treatment C
oral EYP001a
Drug: EYP001a
Capsules administered orally. Number of morning and evening capsules depending on treatment arm

Experimental: Treatment D
oral EYP001a
Drug: EYP001a
Capsules administered orally. Number of morning and evening capsules depending on treatment arm

Placebo Comparator: Treatment E
oral placebo
Drug: Placebo
Placebo capsules for oral administration, identical in appearance to the EYP001a capsules

Active Comparator: Treatment F
oral Entecavir
Drug: Entecavir
Tablets administered orally

Experimental: Treatment G
oral EYP001a plus subcutaneous injection of Peg-INFα2a
Drug: EYP001a
Capsules administered orally. Number of morning and evening capsules depending on treatment arm

Drug: peg-interferon alfa-2a
Ready-to-Use pre-filled syringes for subcutaneous injection

Experimental: Treatment H
oral EYP001a plus subcutaneous injection of Peg-INFα2a
Drug: EYP001a
Capsules administered orally. Number of morning and evening capsules depending on treatment arm

Drug: peg-interferon alfa-2a
Ready-to-Use pre-filled syringes for subcutaneous injection

Placebo Comparator: Treatment I
oral placebo plus subcutaneous injection of Peg-INFα2a
Drug: Placebo
Placebo capsules for oral administration, identical in appearance to the EYP001a capsules

Drug: peg-interferon alfa-2a
Ready-to-Use pre-filled syringes for subcutaneous injection




Primary Outcome Measures :
  1. Type and frequencies of adverse events [ Time Frame: Day 1 through Day 35 ]

Secondary Outcome Measures :
  1. Maximum plasma concentration (Cmax) of EYP001 [ Time Frame: Day 1 through Day 35 ]
  2. Time to reach maximum concentration (Tmax) after EYP001 administration [ Time Frame: Day 1 through Day 35 ]
  3. Area under the concentration-time curve from time 0 to last measurable concentration (AUC0-6h) of EYP001 [ Time Frame: Day 1 through Day 35 ]
  4. Bile acid precursor C4 (7αhydroxy-4-cholesten-3-one) [ Time Frame: Day 1 through Day 35 ]
  5. Fibroblast growth factor 19 (FGF19) [ Time Frame: Day 1 through Day 35 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Have given voluntary written informed consent;
  2. Have a documented medical history of chronic HBV infection (within 12 months of screening visit), both results:

    • Documented positive hepatitis B surface antigen (HBsAg) and
    • Documented HBV DNA > 1000 IU/mL
  3. Is anti-HBV treatment naive or treatment experienced (see also exclusion criterion #3).
  4. Gender: male or female.
  5. Age: 18 to 65 years inclusive.
  6. Body mass index (BMI): 17.0-35.0 kg/m2 inclusive.
  7. Has clinical chemistry, hematology, coagulation and urinalysis tests within normal, allowable limits (with the exception of alanine aminotransferase [ALT]); see inclusion criterion #10); if there is an out of range value, the result must be considered clinically non-significant by the investigator in order to be eligible.
  8. Vital signs after at least 5 minutes resting in supine position at screening within the following ranges:

    • systolic blood pressure: between 90 mm Hg and 145 mm Hg
    • diastolic blood pressure: between 45 mm Hg and 90 mm Hg
    • heart rate: between 40 bpm and 100 bpm
  9. Have no clinically significant abnormal 12-lead automatic electrocardiogram (ECG) (incomplete right bundle branch block can be accepted) at screening: PR interval between 120 ms -and 210 ms, QRS-duration < 120 ms, QTc-interval (Fridericia's) ≤ 450 msec.
  10. ALT at screening ≤ 5 x upper limit of normal (ULN).
  11. Agrees to abstain from all medication, including non-prescription and prescription medication for 28 days prior to the Day 1 study visit, except for authorized medications (such as hormonal contraceptives for females, vitamins prescribed per label dosages and paracetamol). On a case-by-case basis, regular co-medication either as defined on the medication exception list or as documented by written approval from the sponsor as acceptable prior to randomization, will not be considered as a deviation from this criterion.
  12. At screening, females must be non-pregnant and non-lactating, or of non-childbearing potential (either surgically sterilized or physiologically incapable of becoming pregnant, or at least 1 year post-menopausal [amenorrhea duration of 12 consecutive months); non-pregnancy will be confirmed for all females by a pregnancy test conducted at screening and at follow-up visit.
  13. Female subjects of child-bearing potential, with a fertile male sexual partner, should be willing to use adequate contraception from screening until 90 days after the follow-up visit. Adequate contraception is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom. Also, total abstinence, in accordance with the lifestyle of the subject, is acceptable.
  14. Male subjects, if not surgically sterilized, should be willing to use adequate contraception and not donate sperm from the Day 1 visit to the clinical research centre until 90 days after the follow-up visit. Adequate contraception for the male subject (and his female partner) is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom. Also, total abstinence, in accordance with the lifestyle of the subject is acceptable.
  15. At screening, has no recent (<3 months) history of any clinically significant conditions, which, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results.
  16. Willingness to abstain from alcohol from 48 hours prior to each study visit to the clinical research centre.

Exclusion Criteria:

  1. Employee of a CRO participating in this study or the Sponsor.
  2. Has certain or probable compensated liver cirrhosis documented by at least 2 of the following:

    1. Optional assessment: has documented liver histology Metavir score (F4), Ishak >5 or Scheuer (F4)
    2. Mandatory assessment: has presence or history of ascites, spontaneous bacterial peritonitis, esophageal varices, hepatic encephalopathy
    3. Mandatory assessment: platelet count below 90,000/uL within 12 months of screening visit
    4. Optional assessment: positive indirect blood test of APRI or FIB4 or positive direct blood test Fibrosure, Fibrotest, or FibroSpect within 12 months of screening visit
    5. Optional assessment: has positive elastography within 6 months of screening visit (Fibroscan or Shearwave Aixplorer)
    6. Optional assessment: has abnormal liver imaging (CT/US/MRI) consistent with a lobular/nodular liver and cirrhosis or indirect signs of portal hypertension.
  3. Subject is HBV treatment experienced AND currently on anti-HBV treatment during the 30 days (or 5 half-lives of the considered anti-HBV drug, whichever is longer) before the first investigational product administration and until the last study visit.
  4. Co-infection with active hepatitis C virus (HCV, except for patients with sustained viral response SVR, who can be included).
  5. Co-infection with human immunodeficiency virus (HIV) Note: hepatitis D virus (HDV) status is not required for randomization and if not available can be established during the Day 1 visit with baseline PD virology assessments.
  6. Receives or plans to receive systemic immunosuppressive or immunomodulating medications (e.g. IFN) during the study or ≤ 4 months prior to the first investigational product administration.
  7. Has clinically relevant immunosuppression from, but not limited to immunodeficiency conditions such as common variable hypogammaglobulinemia.
  8. Clinical diagnosis of substance abuse during ≤ 12 months prior to screening with narcotics or cocaine or with alcohol (regular consumption > 21 units/week [men] and > 14 units/week [women]; 1 unit = 1⁄2 pint of beer, 25 mL shot of 40% spirit or a 125 mL glass of wine. Expressed in g/day: > 30 g/day [men] and > 20 g/day [women]).
  9. Has a positive drug urine screen (cocaine, phencyclidine, amphetamines (incl. methamphetamines), opiates (incl. heroin, codeine and morphine), benzodiazepines, barbiturates, methadone or alcohol screen. Subjects who admit the occasional use of cannabis will not be excluded as long as they are able to abstain from cannabis when they are assessed at study visits.
  10. Has any known pre-existing medical or psychiatric condition that could interfere with the subject's ability to provide informed consent or participate in study conduct, or that may confound study findings.
  11. Has a history of long QT syndrome.
  12. Has a history of clinically significant gastrointestinal disease, especially peptic ulcerations, gastrointestinal bleeding, ulcerative colitis, Crohn's disease or Inflammatory Bowel Syndrome, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, or cardiovascular disease or any other condition which, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results.
  13. Has participated in any drug study within 40 days prior to the first drug administration in the current study. Note: Part A participation to this study is acceptable and not an exclusion criteria when considering eligibility for Part B, under the condition that follow-up visit of Part A has been completed and no investigational product related SAEs have occurred during Part A.
  14. Has an uncontrolled ongoing illness at screening (e.g., active viral infection).
  15. Has had major surgery within 30 days prior to the first drug administration, or within 6 months for gastrointestinal surgery prior to the first drug administration.
  16. Has a history of relevant drug and/or food allergies.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03272009


Locations
Layout table for location information
Australia, New South Wales
Scientia Clinical Research Limited
Sydney, New South Wales, Australia, 2031
Australia, Western Australia
Linear Clinical Research Limited
Perth, Western Australia, Australia, 6009
Netherlands
Academic Medical Centre (AMC)
Amsterdam, Netherlands
Erasmus MC
Rotterdam, Netherlands
Poland
Klinika Chorób Zakaźnych I Hepatologii UMB
Białystok, Poland
Klinika Chorób Zakaźnych
Kielce, Poland, 25-317
HepID
Lublin, Poland
Thailand
King Chulalongkorn Memorial Hospital
Bangkok, Thailand, 10330
Hospital for Tropical Diseases
Bangkok, Thailand, 10400
Sponsors and Collaborators
Enyo Pharma
CPR Pharma Services Pty Ltd, Australia
Investigators
Layout table for investigator information
Principal Investigator: Henk W Reesink, MD Academic Medical Centre AMC Amsterdam
Principal Investigator: Stephan Riordan Scientia Clinical Research Limited Sydney

Layout table for additonal information
Responsible Party: Enyo Pharma
ClinicalTrials.gov Identifier: NCT03272009     History of Changes
Other Study ID Numbers: EYP001-103
2017-002211-33 ( EudraCT Number )
First Posted: September 5, 2017    Key Record Dates
Last Update Posted: August 21, 2018
Last Verified: August 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis B
Hepatitis B, Chronic
Hepatitis
Liver Diseases
Digestive System Diseases
Hepadnaviridae Infections
DNA Virus Infections
Virus Diseases
Hepatitis, Viral, Human
Hepatitis, Chronic
Interferons
Interferon-alpha
Interferon alpha-2
Entecavir
Peginterferon alfa-2a
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs